A Study Of Efficacy And Safety With Apatinib Or Apatinib Combined With Chemotherapy In Recurrent/advanced Ovarian Cancer Patients
Authors Yang M, Liu X, Zhang C, Liao F, Li Z, Luo X, Sun Y, Chen C
Received 16 July 2019
Accepted for publication 23 September 2019
Published 9 October 2019 Volume 2019:11 Pages 8869—8876
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Eileen O'Reilly
Mi Yang,1,2 Xiufeng Liu,3 Cheng Zhang,4 Feng Liao,3 Zixiong Li,3 Xianwen Luo,3 Yiran Sun,5 Chao Chen3
1The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University, Nanjing 210008, People’s Republic of China; 2Cancer Center of Nanjing Gaochun People’s Hospital, Nanjing 211300, People’s Republic of China; 3Department of Medical Oncology of PLA Cancer Center, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, People’s Republic of China; 4Department of Gynecology, Jiangsu Province Hospital of Chinese Medicine, Nanjing 210029, People’s Republic of China; 5Department of Clinical Medicine, Xuzhou Medicine University, Xuzhou 221004, People’s Republic of China
Correspondence: Chao Chen; Xiufeng Liu
Department of Medical Oncology of PLA Cancer Center, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, People’s Republic of China
Tel +86 25 808 6769
Email email@example.com; firstname.lastname@example.org
Objectives: Despite recent advances in the treatment of advanced ovarian cancer, drug selection after second-line chemotherapy has not been well studied. In this study, we retrospectively evaluated the effect and safety of apatinib as monotherapy or in combination with chemotherapy for the treatment of advanced ovarian cancer after second-line treatment.
Methods: We reviewed the medical records of patients from April 2016 to October 2018 with advanced ovarian cancer who received apatinib after failed second-line chemotherapy. Overall survival (OS) and progression-free survival (PFS) were calculated by the Kaplan–Meier method. Response rate (RR) and disease control rate (DCR) were evaluated using radiologic reports according to RECIST 1.1 criteria. Treatment-related adverse events were evaluated based on NCI-CTC version 4.0.
Results: Study concerned 22 evaluated cases; of them, 13 patients received apatinib combined with chemotherapy and 9 patients received apatinib monotherapy. The median PFS was 8.2 months (9.7 months in combined group and 4.4 months in monotherapy group, P value was 0.21). The median OS was 13.1 months (13.6 months in combined group and 11.6 months in monotherapy group, P value was 0.45). The RR was 20% and DCR was 85% (combined group: RR 33.3%, DCR 100%, monotherapy group: RR 0%, DCR 62.5%). The main side effect was hypertension (9/22), proteinuria (7/22), oral mucositis (5/22), hand and foot syndrome (6/22%), leukopenia (5/22), etc.
Conclusion: Apatinib showed good efficacy and safety for advanced ovarian cancer patients whether used alone or in combination with chemotherapy. In the meanwhile, this study is limited by the small cases number. Therefore, further research is needed to provide more data and ultimately apply it to guide clinical practice.
Keywords: apatinib, chemotherapy, ovarian cancer, efficacy and safety
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]